Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
+$1.20 today
- Market cap
- $56.67M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
Volume 0.15M
Average 0.22M
BOLD Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Boundless Bio, Inc.NASDAQ: BOLD
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares of 22.41M shares rose 0.5% year over year, behind the +7.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.2% from the prior quarter. Over 3 fiscal years it compounded at +0.2% a year.
Context
- Weighted avg shares increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +7.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 22.36M USD
- Year-over-year change
- +31.7%
- 4-year CAGR
- +0.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.36M | +31.7% |
| FY2024 | 2024-12-31 | 16.98M | -23.6% |
| FY2023 | 2023-12-31 | 22.24M | +0.0% |
| FY2022 | 2022-12-31 | 22.24M | +0.0% |
| FY2021 | 2021-12-31 | 22.24M | — |
Weighted Avg Shares vs competitors
How BOLD compares with its peers on the latest reported figures
- BOLD's LTM Mar 2026 weighted avg shares of 22.38M shares is the 2nd highest of the 4 companies compared; the peer median is 12.77M shares.
- Its year-over-year change of +7.1% is the highest of 4, against a peer median of +4.3%.
- Over three fiscal years its annual growth of +0.2% compares with a peer median of +25.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 31.18M | +4.3% | +25.4% | |
| LTM Mar 2026 | 22.38M | +7.1% | +0.2% | |
| LTM Mar 2026 | 12.77M | +5.5% | +56.8% | |
| LTM Mar 2026 | 5.55M | -0.3% | +12.3% | |
| Peer median (excluding BOLD) | 12.77M | +4.3% | +25.4% | |
Competitors are the stored peer set for BOLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.09M | 1.25M |
| Gross Profit | 0 | 0 | 0 | (1.09M) | (1.25M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 19.28M | 37.16M | 42.64M | 55.27M | 44.85M |
| Selling, General & Admin | 6.02M | 9.31M | 12.16M | 18M | 18.71M |
| Operating Expenses | 25.3M | 46.47M | 54.8M | 72.18M | 62.3M |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| EBITDA | (24.53M) | (44.96M) | (48.48M) | (64.28M) | (56.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (25.3M) | (46.47M) | (54.8M) | (73.27M) | (63.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 96K | 668K | 5.28M | 7.89M | 5.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 91K | 568K | 5.36M | 7.9M | 5.36M |
| Income Before Tax | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| EPS (Diluted) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| Weighted Avg Shares | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M |
| Weighted Avg Shares (Diluted) | 22.24M | 22.24M | 22.24M | 16.98M | 22.36M |
Boundless Bio, Inc.
NASDAQ:BOLD
Intrinsic Alpha fair value
Locked
Current Price
$2.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.